EX-99.1 2 rsls-20210816xex99d1.htm EX-99.1

Graphic

Exhibit 99.1

ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update

Webinar to follow at 8:30 a.m. today

San Clemente, CA August 16, 2021 — ReShape Lifesciences Inc. (NASDAQ: RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its financial and operational results for the three months ended June 30, 2021.

Recent Highlights and Accomplishments

Successfully completed merger with Obalon Therapeutics positioning ReShape as major leader in weight loss market
Began trading June 16 on Nasdaq Capital Market under ticker RSLS
Transition of Lap-Band manufacturing from previous owners to US-based manufacturer under our operational oversight
Completed funding round raising gross proceed of $46 million; eliminated debt overhang; removed any and all liens against our assets and now leveraging stronger balance sheet
Introduced ReShape MarketplaceTM; digital health solution adding to proprietary ecosystem of weight loss products
Witnessed an increase in Lap-Band procedures among practices

Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences, commented, “As indicated by our preliminary results, the second quarter proved to be monumental for the Company. During this period, we completed our highly anticipated merger with Obalon Therapeutics, increased visibility in the financial markets by listing on the Nasdaq and bolstered our diverse product portfolio with the launch of our online wellness hub, ReShape MarketPlace. In addition, we restructured our balance sheet closing a $46 million funding round which has now enabled our team to focus on further growth initiatives within the weight loss industry.”

Mr. Bandy continued, “Additionally, we proactively addressed operational efficiency concerns by shifting the manufacturing of the Lap-Band to a US-based firm. We believe this series of positive events clearly indicate a path of positive transformation for ReShape.”


Graphic

Second Quarter 2021 Financial Results

Revenue for the three months ended June 30, 2021, was $3.5 million compared to $1.7 million in revenue for the three months ended June 30, 2020. The $1.8 million increase was primarily due to greater US sales. Revenues grew 10% from the 1st Quarter 2021 representing increases in both US and OUS revenues.

Gross profit for the second quarter of 2021 was $2.1 million compared to $0.8 million for the three months ended June 30, 2020.

Sales and marketing expenses for the three months ended June 30, 2021 were $1.4 million compared to $0.8 million for the three months ended June 30, 2020.

General and administrative expenses were $4.3 million for the second quarter of 2021 compared to $2.5 million for the three months ended June 30, 2020.

Research and development expenses were $0.1 million for the second quarter of 2021 compared to $0.5 million for the three months ended June 30, 2020.

Total operating expenses were $5.9 million for the second quarter of 2021 compared to $3.8 million for the three months ended June 30, 2020.

Non-GAAP adjusted EBITDA loss was $1.2 million for the second quarter of 2021 compared to a loss of $2.1 million for the three months ended June 30, 2020.

Cash and cash equivalents and restricted cash were $40.2 million as of June 30, 2021.

Webinar Information

Management will post a webinar discussing ReShape's financial and operational results today at 8:30 a.m. ET. The link to the webinar is here and will be available on the Investor Relations page of the ReShape Lifesciences, Inc. website, https://ir.reshapelifesciences.com/.

About ReShape Lifesciences, Inc. 
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare ™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals.

Forward-Looking Safe Harbor Statement:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These and additional risks and uncertainties are described more fully in the company’s filings with the Securities and Exchange Commission, including those factors identified as “risk factors” in our Annual Report on Form 10-K and in our subsequent Quarterly Report on Form 10-Q.


Graphic

Non-GAAP Disclosures

In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in this Form 10-K have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

Adjusted EBITDA

Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, changes in fair value of liability warrants and other one-time costs. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

CONTACTS: 
ReShape Lifesciences Investor Contact: 
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts: 
Daniel Kontoh-Boateng
Assistant Vice President
The Ruth Group
646-536-7019
dboateng@theruthgroup.com


Graphic

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Balance Sheets

(dollars in thousands, except per share amounts; unaudited)

June 30, 

December 31, 

    

2021

    

2020

ASSETS

Current assets:

Cash and cash equivalents

$

40,163

 

$

2,957

Restricted cash

50

50

Accounts and other receivables

 

3,422

 

 

2,620

Inventory

 

2,894

 

 

2,244

Deferred stock issuance costs*

17,705

Prepaid expenses and other current assets

 

1,371

 

 

1,073

Total current assets

 

65,605

 

 

8,944

Property and equipment, net

 

1,588

 

 

584

Operating lease right-of-use assets

632

465

Other intangible assets, net

28,924

27,022

Goodwill

21,623

Other assets

 

1,628

 

 

46

Total assets

$

120,000

 

$

37,061

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

3,095

 

$

3,655

Accrued and other liabilities*

 

53,333

 

 

3,630

Warranty liability, current

468

397

Debt, current portion, net of deferred financing costs

2,936

3,609

Operating lease liabilities, current

664

314

Total current liabilities

 

60,496

 

 

11,605

Debt, noncurrent portion

9,168

Operating lease liabilities, noncurrent

163

Warranty liability, noncurrent

732

1,022

Deferred income taxes

615

615

Other liabilities

38

Total liabilities

61,881

 

22,573

Commitments, contingencies and subsequent events

Stockholders’ equity:

Preferred stock:

Series B convertible preferred stock

Series C convertible preferred stock

1

Common stock

 

8

 

 

6

Additional paid-in capital

 

581,823

 

 

529,429

Accumulated deficit

 

(523,603)

 

 

(514,827)

Accumulated other comprehensive loss

(109)

(121)

Total stockholders’ equity

 

58,119

 

 

14,488

Total liabilities and stockholders’ equity

$

120,000

 

$

37,061

* Relates to the shares not issued in conjunction with the June 28, 2021 warrant exercise agreement, prior to the quarter ended June 30, 2021. Since the shares are in abeyance, an accrual of $43.2 million was recorded, along with $17.7 million in deferred issuance costs. This will be recognized against equity during the quarter ended September 30, 2021.


Graphic

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Operations

(dollars in thousands, except per share amounts; unaudited)

Three Months Ended June 30, 

Six Months Ended June 30, 

2021

2020

    

2021

2020

Revenue

$

3,529

$

1,702

$

6,750

$

4,491

Cost of revenue

1,376

 

865

 

2,314

 

2,150

Gross profit

2,153

 

837

 

4,436

 

2,341

Operating expenses:

Sales and marketing

1,441

 

831

 

2,691

 

2,285

General and administrative

4,311

2,539

7,031

5,375

Research and development

103

 

465

 

674

 

1,761

Total operating expenses

5,855

 

3,835

 

10,396

 

9,421

Operating loss

(3,702)

 

(2,998)

 

(5,960)

 

(7,080)

Other expense (income), net:

Interest expense, net

172

789

771

893

Loss on extinguishment of debt, net

101

2,061

Loss (gain) on foreign currency exchange, net

(101)

(133)

(69)

10

Loss before income tax provision

(3,874)

(3,654)

(8,723)

(7,983)

Income tax expense (benefit)

28

(50)

53

(68)

Net loss

$

(3,902)

$

(3,604)

$

(8,776)

$

(7,915)

Net loss per share - basic and diluted:

Net loss per share - basic and diluted

$

(0.47)

$

(0.52)

$

(1.11)

$

(1.15)

Shares used to compute basic and diluted net loss per share

8,226,144

 

6,911,497

 

7,928,702

 

6,885,368

The following table contains a reconciliation of non-GAAP net loss to GAAP net loss attributable to common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands):

Three Months Ended June 30, 

Six Months Ended June 30, 

2021

2020

2021

2020

GAAP net loss

$

(3,902)

$

(3,604)

$

(8,776)

$

(7,915)

Adjustments:

Interest expense, net

172

789

771

893

Income tax expense (benefit)

28

(50)

53

(68)

Depreciation and amortization

450

418

868

838

Stock-based compensation expense

(364)

347

(263)

774

Loss on extinguishment of debt, net

101

2,061

Professional fees incurred in connection with the Obalon merger

2,277

2,277

Non-GAAP loss

$

(1,238)

$

(2,100)

$

(3,009)

$

(5,478)